香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 海外監管公告 国药控股股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 公司债券中期报告 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 （2025 年） 二〇二五年八月 0 国药控股股份有限公司公司债券中期报告（202 ...

Core Viewpoint - Xinhua Medical's stock price closed at 17.33 yuan on August 20, 2025, reflecting a 0.70% increase from the previous trading day [1] Company Overview - Xinhua Medical specializes in the manufacturing of medical devices, including the research, production, and sales of medical equipment and consumables [1] - The company's products are widely used in hospitals, clinics, and other medical institutions [1] Market Performance - On August 20, 2025, Xinhua Medical opened at 17.12 yuan, reached a high of 17.33 yuan, and a low of 17.06 yuan, with a trading volume of 142,700 shares and a total transaction value of 245 million yuan [1] - Over the past five trading days, the cumulative net outflow of funds from Xinhua Medical reached 162 million yuan, with a net outflow of 23.66 million yuan on August 20 [1]

Core Viewpoint - Beijing Medical Pharmaceutical Company (北大医药) is facing significant challenges as its wholly-owned subsidiary, Beijing Beiyi Medical Co., Ltd. (北医医药), will terminate its long-term service contract with Peking University International Hospital (国际医院) in May 2025, leading to substantial revenue and profit declines [1][5][6] Group 1: Contract Termination and Financial Impact - The long-term service contract between 北医医药 and 国际医院, which has been in place for three years, is set to end in May 2025, resulting in a projected revenue decrease of approximately 600 million yuan (about 6 billion) and a net profit reduction of around 40 million yuan (about 4000) [1][4] - The termination of the contract is expected to cause a significant operational strain on the company, with potential layoffs and a shift in business focus [5][6] Group 2: Future Business Direction and Risks - Following the termination, 北医医药 has not identified alternative business opportunities, which raises concerns about a complete halt in its main operations and the risk of company closure or transformation [5][6] - The company anticipates a further revenue decline of approximately 1.027 billion yuan (about 10.27 billion) and a net profit decrease of around 68.69 million yuan (about 6869) starting in 2026, which could represent nearly 50% of its most recent audited revenue and profit figures [6]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), participated in recent bidding for medical consumables procurement projects in Jiangsu Province and the renewal procurement projects for indwelling needles and foam dressings in Shaanxi Province [1] Group 1 - Kelong Medical is involved in the bidding for the seventh and eighth rounds of medical consumables procurement in Jiangsu Province [1] - The company is also participating in the renewal procurement for indwelling needles and foam dressings in Shaanxi Province [1] - The results indicate that Kelong Medical's products are expected to be selected for these centralized procurement projects [1]

Group 1 - The stock price of Jinhai Medical as of August 6, 2025, is 24.98 yuan, down 0.50 yuan from the previous trading day's closing price, representing a decline of 1.96% [1] - The opening price for the day was 25.50 yuan, with a highest price of 25.55 yuan and a lowest price of 24.67 yuan, resulting in a trading volume of 24,581 hands and a transaction amount of 0.62 billion yuan [1] - Jinhai Medical operates in the medical device industry, focusing on the research, production, and sales of medical devices, with products spanning various medical fields including rehabilitation care and medical consumables [1] Group 2 - On August 6, a block trade occurred involving 100,000 shares at a transaction amount of 2.411 million yuan, with a transaction price of 24.11 yuan, which is a discount of 3.48% relative to the day's closing price [1] - The buyer of this block trade was Guoxin Securities Shandong Branch, while the seller was GF Securities Huizhou Xiapu Road Branch [1] - In the past month, Jinhai Medical has recorded a total of 6 block trades, with a cumulative transaction amount of 18.1655 million yuan [1]

Group 1 - The stock price of Kefu Medical reached 38.51 yuan as of August 4, 2025, with an increase of 0.12 yuan, representing a rise of 0.31% [1] - The trading volume on that day was 37,018 hands, with a transaction amount of 141 million yuan and a fluctuation of 4.56% [1] - Kefu Medical operates in the medical device industry, focusing on the research, production, and sales of medical equipment and consumables [1] Group 2 - As of July 31, 2025, Kefu Medical had approximately 19,000 shareholders [1] - The company is one of the 17 A-share listed companies that announced plans for an IPO in Hong Kong in July [1] - On August 4, the net inflow of main funds into Kefu Medical was 6.59 million yuan, accounting for 0.09% of the circulating market value [1] Group 3 - Over the past five trading days, the cumulative net inflow of main funds was 49.34 million yuan, representing 0.66% of the circulating market value [1]

采纳股份主营业务为医疗器械的研发、生产和销售，产品涵盖医用耗材、医疗设备等领域。公司所属板 块包括医疗器械、创业板综等。 截至2025年7月31日收盘，采纳股份股价报22.79元，较前一交易日下跌0.70%，成交额0.69亿元，换手 率4.46%。盘中振幅4.05%，最高触及23.62元，最低下探22.69元。 消息面上，公司公告称2025年第三次临时股东会审议通过了《关于补选第三届董事会非独立董事的议 案》。 风险提示：市场有风险，投资需谨慎。 资金方面，7月31日主力资金净流出194.29万元，占流通市值的0.13%。 ...

Core Insights - The Zhengzhou Aviation Port Economic Comprehensive Experimental Zone has rapidly developed the Central Plains Medical Science City, a key part of the "Shuanghe Lake Sci-Tech Corridor" within two years [1][3] - The corridor spans 20 kilometers and covers over 200 square kilometers, linking various key areas including the Central Plains Medical Science City and advanced manufacturing clusters [1] Group 1: Project Development - The Central Plains Medical Science City has attracted 263 biopharmaceutical companies and signed 88 key projects [1] - Major projects include the intelligent rehabilitation equipment manufacturing center by Ruibei Medical Technology Co., aiming for an annual production of over 10,000 units [3] - The medical consumables R&D and production base by Zhengzhou Gongdong Medical Devices Co. has a total investment of 300 million yuan and will cater to both domestic and international markets [3] Group 2: Industry Collaboration - The city promotes a "five-chain" integration model, combining innovation, funding, talent, policy, and industry [6] - The establishment of 11 clinical research institutes and 4 provincial laboratories enhances research capabilities [6] - The collaboration within the corridor allows for a significant reduction in research and development cycles, shortening them by over 30% [6] Group 3: Urban Development - The construction of supporting infrastructure, including a star-rated hotel and a comprehensive road network, is underway [8] - The region has developed 6,000 talent apartments and is set to launch commercial facilities by September [8] - By 2025, the Central Plains Medical Science City aims to establish a 100 billion yuan biopharmaceutical industry cluster, enhancing the pharmaceutical industry's capabilities in Henan [8]

Group 1 - The company expects a net profit to be negative for the period from January 1, 2025, to June 30, 2025 [2] - The revenue from completed medical engineering projects has decreased by 72% compared to the same period last year, leading to significant losses [3] - Sales and profit margins of exported medical consumables have further declined, contributing to the overall financial downturn [3] Group 2 - Government subsidies and the write-off of receivables have resulted in a decrease of approximately 90% in non-operating income compared to the previous year [3] - The financial data for the first half of 2025 is based on preliminary estimates by the company's finance department and has not been audited [4] - The company will disclose detailed financial data in the "2025 Semi-Annual Report" and emphasizes the importance of timely information disclosure [4]

Group 1 - Liu Zhongliang, former president and party secretary of the Shanyang County People's Hospital, was sentenced to two and a half years in prison for accepting bribes totaling approximately 1.262 million yuan [2][3][4] - The bribes were received from 16 individuals, including a manager from a subsidiary of Ruikang Pharmaceutical, to gain advantages in medical equipment procurement and supply of consumables [2][5][6] - Ruikang Pharmaceutical's subsidiary, Ruikang Pharmaceutical (Shaanxi) Medical Device Co., Ltd., was implicated in the bribery case, although the company denied any knowledge of the alleged bribe [7][8] Group 2 - Ruikang Pharmaceutical is a comprehensive medical service provider listed on the A-share market, with a peak revenue exceeding 35 billion yuan in 2019, but has faced a continuous decline in revenue, reporting around 8 billion yuan in 2024 [7] - The company has experienced a net profit loss for four consecutive years, with a reported loss of 128 million yuan in 2024 [7] - Recently, Ruikang Pharmaceutical's board member and vice president was placed under investigation, indicating potential ongoing issues within the company's management [8]